The FB23-everolimus combination synergistically inhibits pancreatic neuroendocrine tumors 15; similarly, the combination of FB23 and BX-912 targets FTO and the PDK1-AKT pathway to suppress breast cancer 16. Here, AKT1 is linked to pancreatic neuroendocrine tumor.